Mainz Biomed N.V. has announced a partnership with Quest Diagnostics to commercialize its stool-based colorectal cancer screening test, ColoAlert, which detects tumor DNA to identify early-stage ...
From expanding partnerships to advancing trials, Mainz Biomed NV (NASDAQ:MYNZ), the molecular genetics diagnostic company, had a busy 2024 – which appears to have shown in its revenue growth. The ...
Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Mainz Biomed B.V. ( (MYNZ)) has ...
BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ...
With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving ...
InTray GC plays a crucial role in the timely and precise identification of Neisseria gonorrhoeae, the bacteria behind the widespread sexually transmitted infection, gonorrhea. DCN Dx, based in ...
Pick the best stocks and maximize your portfolio: Mainz Biomed B.V. ( (MYNZ)) has provided an announcement. Mainz Biomed announced the pricing of an $8 million follow-on offering, with each unit sold ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results